Efficacy and Safety of SPN-812 (Extended-Release Viloxazine) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis.
Xin TanYuejuan XuShixin WangJiaxuan LiChunxia HuZhouqing ChenQingzhang ChengZhong WangPublished in: Brain sciences (2023)
At present, SPN-812 (100, 200, and 400 mg/d) is superior to the corresponding control in efficacy measures. However, the safety problem cannot be ignored.
Keyphrases